The clinical relevance of preclinical data: Mirtazapine, a model compound

Journal of Clinical Psychopharmacology

Volumn 17, Issue 2 SUPPL. 1, 1997, Pages

  Delbressine, Leon P C ^a   Vos, Ria M E ^a  

^a NV ORGANON   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; MIRTAZAPINE;

BIOTRANSFORMATION; CONFERENCE PAPER; DEPRESSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL;

ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; BRAIN; CYTOCHROME P-450 ENZYME SYSTEM; DEPRESSIVE DISORDER; HALF-LIFE; HUMANS; LIVER; METABOLIC CLEARANCE RATE; MIANSERIN; POLYMORPHISM, GENETIC; PROTEIN BINDING;

EID: 0030906584     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Davis R, Wilde MI. Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs 1996;5:398-402.
2. 1A-mediated serotonergic neurotransmission. CNS Drugs 1995;4[suppl 1]:29-38.
3. Smith DA. Design of drugs through a consideration of drug metabolism and pharmacokinetics. Eur J Drug Metab Pharmacokinet 1994;3:193-9.
4. 2-adrenoceptor blockade in the central nervous system and the effects of the enantiomers of mianserin and its aza-analog Org 3770. Arch Int Pharmacodyn Ther 1988;291:185-201.
5. Lin JH. Species, similarities and differences in pharmacokinetics. Drug Metab Dispos Biol Fate Chem 1995;23:1008-21.
6. Rolan PE. Plasma protein binding displacement interactions. Br J Clin Pharmacol 1994;37:125-8.
7. Samson LN, Evans AM. What is the true clinical significance of plasma protein binding displacement interactions. Drug Saf 1995; 12:227-33.
8. Voortman G, Paanakker JE. Bioavailability of mirtazapine from Remeron tablets after single and multiple oral dosing. Hum Psychopharmacol 1995;10[suppl 2]:S83-96.
9. Sandker GW, Vos RME, Delbressine LPC, Slooff MJH, Meijer DKF, Groothuis GMM. Metabolism of three pharmacologically active drugs in isolated human and rat hepatocytes: analysis of interspecies variability and comparison with metabolism in vivo. Xenobiotica 1994;24:143-55.
10. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23.
11. Meyer UA, Amrein R, Balant LP, Bertilsson L, Eichelbaum M, Guentert TW, Henauer S, Jackson P, Laux G, Mikkelsen H, Peck C, Pollock BG, Priest R, Sjöqvist F, Delini-Stula A. Antidepressants and drug-metabolizing enzymes-expert group report. Acta Psychiatr Scand 1996;93:71-9.
12. Harvey AT, Preskom SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin uptake inhibitors. Part I. J Clin Psychopharmacol 1996;16: 273-85.
13. Schmider J, Greenblatt DJ, von Moltke LL, Shader RI. Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: implications for diazepam disposition in humans. J Clin Psychopharmacol 1996;16:267-72.
14. Timmer CJ, Lohmann AAM, Mink CPA. Pharmacokinetic doseproportionality study at steady state of mirtazapine from Remeron® tables. Hum Psychopharmacol 1995;10[suppl 2]:97-106.
15. Segel IH. Behavior and analysis of rapid equilibrium and steady-state enzyme systems. In: Enzyme kinetics. New York: John Wiley, 1975:100-226.
16. Dahl M-L, Voortman G, Aim C, Delbressine L, Vos R, Bogaards JJP, Bertilsson L. In vitro and in vivo studies on the disposition of mirtazapine in man. Clin Drug Invest 1997;13:37-46.